Company: GEHC
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001932393-25-000053
Chunk: 57

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 1
Chunk 57
---
17 %79920.9 %74420.2 %7 %PCS    273.7 %8210.6 %(67)%1356.0 %24110.5 %(44)%PDx    22029.4 %19330.9 %14 %63830.3 %57130.6 %12 %

____________________

*Non-GAAP Financial Measure

36

For the three months ended September 30, 2025

•Imaging Segment EBIT was $240 million, a decrease of $46 million due to cost inflation, including the impact of incremental tariffs, partially offset by a growth in sales volume;

•AVS Segment EBIT was $271 million, an increase of $40 million due to growth in sales volume and cost productivity, partially offset by cost inflation, including the impact of incremental tariffs;

•PCS Segment EBIT was $27 million, a decrease of $55 million due to a decline in sales volume, cost inflation, including the impact of incremental tariffs, and unfavorable mix; and

•PDx Segment EBIT was $220 million, an increase of $27 million due to an increase in price and growth in sales volume, partially offset by increased investment.

For the nine months ended September 30, 2025

•Imaging Segment EBIT was $627 million, a decrease of $33 million due to cost inflation, including the impact of incremental tariffs, partially offset by a growth in sales volume, cost productivity, and an increase in price;

•AVS Segment EBIT was $799 million, an increase of $55 million due to growth in sales volume and cost productivity, partially offset by cost inflation, including the impact of incremental tariffs;

•PCS Segment EBIT was $135 million, a decrease of $106 million due to cost inflation, including the impact of incremental tariffs, unfavorable mix, and a decline in sales volume; and

•PDx Segment EBIT was $638 million, an increase of $68 million due to an increase in price and growth in sales volume, partially offset by increased investment.

NON-GAAP FINANCIAL MEASURES

The non-GAAP financial measures presented in this Quarterly Report on Form 10-Q are supplemental measures of our performance and our liquidity that we believe will help investors understand our financial condition, cash flows, and operating results, and assess our future prospects. When read in conjunction with our U.S. GAAP results, these non-GAAP financial